ideasIdea

Peritoneal-directed therapy for gastric cancer

Stomach cancer usually comes back on the abdominal lining, where drugs barely reach. Deliver treatment directly into the abdomen.

Intraperitoneal paclitaxel with systemic chemotherapy (PHOENIX-GC narrowly missed; Japanese follow-up trials), PIPAC, and regionally delivered CLDN18.2 CAR-T target the compartment systemic therapy misses. Staging laparoscopy with cytology identifies candidates early.

Hypothesis

Adding intraperitoneal paclitaxel to systemic chemotherapy-immunotherapy improves OS in patients with peritoneal-only metastases.

Rationale

Pharmacokinetic advantage of intraperitoneal delivery; peritoneal-only disease is a distinct, chemoresistant compartment.

What would test it

Randomised phase 3 restricted to peritoneal-only disease by laparoscopy; OS primary.

Maturity

early clinical

Connected

6top

Pages like this

not linked directly; found by shared links

Peritoneal-directed therapy for gastric cancer

Connected

Pages like this

cancers

technologies

drugs

terms

bottlenecks